The Cureus Journal of Medical Science is proud to introduce the Surgically Targeted Radiation Therapy for Brain Tumors: Clinical Case Review competition.
Surgically targeted radiation therapy is an important intraoperative brain tumor treatment for patients with newly diagnosed malignant and recurrent brain tumors, including brain metastases, aggressive meningiomas, and gliomas. Surgically targeted radiation therapy involves the implantation of radioactive sources within the surgical bed at the time of brain tumor resection thereby allowing an immediate, dose-intensive treatment inside the area most at risk for recurrence. Awards will be granted to the highest-rated case report in each histology: glioma, meningioma, and brain metastases.
To encourage continued research and knowledge sharing focused on recent advances in surgically targeted radiation therapy for brain tumors, we are seeking case reports and case series that explore and document clinical results for brain tumors.
Results will be shared with the broad surgical community worldwide and all published materials will be Open Access and indexed with PubMed Central. We encourage any surgeon or clinician in the surgical community to contribute!
Program administration has been enabled through the financial support of GT Medical Technologies. Article selection, editorial review, peer review, publication and competition winner determination are strictly independent of the sponsor.
Peer Review Panel
All article submissions will undergo independent pre-publication peer review conducted by a world-class team of experts.
Stuart LeeM.D. | Neurological Surgery
Neurosurgery, Vidant Medical Center, Greenville, USA
Kimberly HoangM.D. | Neurological Surgery
Neurosurgery, Emory University School of Medicine, Atlanta, USA
Erin M. DunbarM.D. | Oncology
Neuro-Oncology & Palliative Care, Piedmont Brain Tumor Center, Atlanta, USA
Thomas H. BeckhamPh.D., M.D. | Radiation Oncology
Radiation Oncology, MD Anderson Cancer Center, Houston, USA
Ronald ReimerM.D. | Neurological Surgery
Neurological Surgery, Mayo Clinic (Emeritus), Jacksonville, USA
Yazmin OdiaM.D. | Neurology
Neuro-Oncology, Miami Cancer Institute, Miami, USA
Richard CrownoverPh.D., M.D. | Radiation Oncology
Department of Radiation Oncology, University of Arkansas for Medical Sciences College of Medicine, Little Rock, USA
Aidnag DiazProfessor, M.D. | Radiation Oncology
Department of Radiation Oncology, St. Joseph’s Hospital and Medical Center, Phoenix, USA
Adam NowlanM.D. | Radiation Oncology
Department of Radiation Oncology, Piedmont Hospital, Atlanta, USA
Alexander MasinoPh.D., M.D. | Radiation Oncology
Radiation Oncology, Columbus CyberKnife, Columbus, USA
Ryan DuBoseM.Sc. | Medical Physics
Medical Physics, Carolina Regional Cancer Center, Myrtle Beach, USA
Joseph M. ZabramskiProfessor, M.D. | Neurological Surgery
Neurosurgery, Barrow Neurological Institute, Phoenix, USA
John E. WaneboM.D. | Neurological Surgery
Neurosurgery, Barrow Neurological Institute, Phoenix, AZ, USA
Karen FinkPh.D., M.D. | Neurology
Neuro-Oncology Associates, Baylor Scott and White Health, Dallas, USA
The entry period is now closed. Competition entries appear below as they are published. Now is your chance to score and discuss these articles. Honorariums will be awarded to the highest-scoring glioma, meningioma and brain metastases cases!
Competition entry and article submission is entirely free. All submitted work must be previously unpublished. Only case reports/series are eligible for submission.
All articles must be submitted and formatted via the template-driven, self-publishing Cureus platform. Authors are encouraged to include supporting images, charts, tables and/or videos within their article submissions. For additional information on publishing with Cureus, please refer to our Author Guide.
- All clinical studies must be compliant with applicable regulatory, ethics / IRB, and other rules governing protection of human subjects.
- All non-clinical studies must be compliant with applicable AAUC, AAALAC, and other related regulations.
- This program is not intended to promote or otherwise encourage unapproved, un-cleared use of products or any product for unapproved new use.
- This program in no way promotes or purports to encourage any research that is not in compliance with any local, federal, or other applicable governing laws.
Statement of Independence
Cureus Publishing Competitions are intended to encourage medical discovery and document clinical experiences – be they positive, negative, or neutral and foster broader educational outreach through Open Access publication that is free to both authors and readers.
Article submissions must adhere to the described “call for articles” and are open to any and all related manufacturer or vendor technologies.
As a firewall to ensure objective and credible science, article selection, editorial review, peer review and publication are strictly independent of the sponsoring company.
Winning articles are selected exclusively via peer review panel and community crowdsourced scoring. Neither the sponsoring company, nor Cureus, can determine the competition outcome.
Winning Article Awards
One case from each of the three categories (glioma, meningioma, brain metastases) will be awarded an honorarium for Cureus Scientific Excellence™ which will be determined by Cureus SIQ™ (Scholarly Impact Quotient™) ratings.
- $3,000 USD for the highest-rated glioma case
- $3,000 USD for the highest-rated meningioma case
- $3,000 USD for the highest-rated brain metastases case
Subsequent to a formal editorial and peer review, published articles undergo SIQ scoring - Cureus’ unique crowdsourced, secondary peer-review process. In addition to measuring engagement, SIQ allows the community-at-large to rate the quality of individual articles. Reviewers assign scores from 1 to 10 on criteria including clarity and rationale, clinical importance, study design and methods, data analysis, novelty of conclusions and quality of presentation.
Aggregated community SIQ scores allow clinicians and researchers to quickly assess article quality in a manner similar to that of Amazon® and Yelp® community reviews.
Eligible articles must receive a minimum of 5 scores. (A Cureus user can assign only one score per article.) As engagement and scoring is critical to winning, authors are highly encouraged to share their published articles via social media and email.
Sunshine Act Reporting
Section 6002 of the Affordable Care Act requires applicable manufacturers of covered drugs, devices, biologicals, and medical supplies to report payments or other transfers of value made to physicians and teaching hospitals. For winning article and referral awards paid to “covered recipients,” award fees shall be supplied to KCI for subsequent Sunshine Act reporting.
- Tuesday, July 27, 2021 – Competition begins; articles may now be submitted.
- Tuesday, November 2, 2021 – Article submission deadline @ 5:00 pm ET (DEADLINE EXTENDED!)
- Tuesday, November 16, 2021 – Peer review of all eligible articles concludes.
- Tuesday, December 21, 2021 – Crowdsourced scoring (SIQ) complete @ 5:00 pm ET
- Thursday, December 23, 2021 – Winning articles announced